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Preclinical evaluation of the simultaneous inhibition
of MCL-1 and BCL-2 with the combination of S63845
and venetoclax in multiple myeloma 
Apoptotic evasion has been postulated as one of the
main mechanisms of multiple myeloma (MM) cell sur-
vival.1,2 The intrinsic apoptotic pathway, tightly regulated
by the BCL-2 protein family, is initiated by intracellularly
sensed stress signals and ultimately leads to the perme-
abilization of the outer mitochondrial membrane. Tumor
cells can keep this pathway  inactivated, in part, through
the overexpression of BCL-2, BCL-XL or MCL-1 anti-
apoptotic proteins,3 which bind to and sequester pro-
apoptotic proteins (e.g. BIM, NOXA, PUMA), thereby
eluding apoptosis. Venetoclax is a drug that selectively
binds to BCL-2, impeding its activity as an inhibitor of
pro-apoptotic proteins.4 In MM, a phase I clinical trial of
venetoclax in monotherapy (clinicaltrials.gov identifier:
01794520) has been effective, predominantly in the sub-
group of patients harboring the t(11;14) translocation.5
Although co-dependencies with BCL-2 and BCL-XL have
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Figure 1. S63845 strongly synergizes with venetoclax in vitro. (A) Multiple myeloma (MM)  cell lines were exposed to increasing doses of S63845+venetoclax
for 48 hours (h), using a constant drug ratio combination design for each cell line. Apoptosis induction was analyzed by flow cytometry after Annexin-V binding
and propidium iodide micromolar staining as represented in the graphs, and combination indices (CI) were calculated with the Calcusyn software (see also
Online Supplementary Figure S2). A CI of 1 indicates an additive effect, CI <1 a synergistic effect and CI<1 antagonism. (B) MM.1S cells were treated with
S63845 50 nM and venetoclax 2.5 nM for 3, 6, 12, 24 and 48 h, and the induction of apoptosis was assessed at indicated time points. (C) Bone marrow cells
from eight MM patients were incubated with S63845 and venetoclax as single agents and in combination at indicated doses for 24 h. Apoptosis induction was






Figure 2. The S63845 + venetoclax combination impairs the interactions of MCL-1 and BCL-2 with the pro-apoptotic protein BIM. (A) BIM shows three major
isoforms: BIMEL, BIML and BIMS. MM.1S clones KO for BIMEL and BIML isoforms were generated by electroporation of a Cas9 ribonucleoprotein complex [contain-
ing a guide RNA and a Cas9 enzyme (Integrated DNA Technologies)], using the Neon Transfection System (Thermo Fisher Scientific) and subsequent single cell
sorting. Clones KO for BIMEL and BIML isoforms and control clones (electroporated with the Cas9 enzyme only) were exposed to increasing doses of
S63845+venetoclax for 24 hours, keeping a constant 1:50 S63845:venetoclax ratio. Cell viability was analyzed by MTT assay. (B and C) MM.1S and KMS12-
BM cell lines (least sensitive and most sensitive to S63845 and venetoclax) were respectively treated with S63845 (12.5 and 2 nM) and venetoclax (625 and
4 nM), in monotherapy or in combination for 24 hours (S63845 and venetoclax doses were adjusted for each cell line so that the combination would induce
13-25% apoptosis as measured by Annexin-V and PI staining). Protein lysates were subjected to immunoprecipitation with an anti-BIM antibody, and MCL-1, BCL-
2 and BCL-XL bound to BIM were then analyzed by immunoblotting. Their levels were quantified by densitometry analysis of bands using ImageJ software, nor-






Figure 3. The S63845 + venetoclax combination has potent in vivo anti-myeloma activity. (A) In vivo efficacy of S63845+venetoclax in an RPMI-8226-luc
xenograft model of disseminated multiple myeloma (MM) in BRG mice. Experimental groups included: control (vehicle), S63845 (12.5 mg/kg intravenous, week-
ly), venetoclax (100 mg/kg oral administration, 5 days per week), and the respective combination (n=4 per group). Mice were treated until death or sacrifice for
humane reasons. Statistically significant differences (Kruskal-Wallis test followed by Dunn's post-hoc comparisons, *P<0.05) were observed from day 19
onwards when comparing the combination with the control. Data are summarized as the mean±Standard Error of Mean (SEM). (B) Images representing the bio-
luminescence signal of each mouse by treatment group from day 5 to day 33 of treatment. (C) Kaplan-Meier curves representing the survival of each treatment
group. (D) Efficacy of the triple combination S63845+venetoclax+dexamethasone using the doses and scheme as in (A) but with intraperitoneal dexamethasone
administration (1 mg/kg, 2 days/week) (n=3 per group). Data are shown as mean±SEM. (E) RPMI-8226 cells were subcutaneously injected in CB17-SCID mice.
When plasmacytomas reached 2 cm in one of their diameters, animals received one dose of vehicle, S63845 (12.5 mg/kg), venetoclax (100 mg/kg) or the
respective combination (n=2 per group). Tumors were excised 24 hours after treatment and protein lysates from tumors were subjected to immunoprecipitation
with an anti-BIM antibody. MCL-1, BCL-2 and BCL-XL anti-apoptotic proteins bound to BIM were then analyzed by immunoblotting, quantified by densitometry




been described,6,7 MM cells are heavily dependent on
MCL-18,9 and high levels of MCL-1 have been associated
with venetoclax resistance.2,10 In this regard, a new selec-
tive MCL-1 inhibitor, S63845, has recently demonstrated
single-agent anti-tumor effect in MM.11 Within this sce-
nario, we sought to test the potential synergistic apoptot-
ic induction of S63845 and venetoclax in MM.
Mechanistically, the shift in MM-cell dependence to dif-
ferent anti-apoptotic proteins observed with each agent
in monotherapy was greatly overcome with the double
combination, translating into important anti-myeloma
efficacy in vitro, ex vivo and in vivo. 
We selected five myeloma cell lines with different sen-
sitivities to S63845 and venetoclax in monotherapy
(MM.1S being the most resistant and KMS12-BM the
most sensitive), and evaluated the cytotoxic effect of the
combination of both agents by flow cytometry (Figure
1A) and MTT assay (Online Supplementary Figure S1).
Overall, our in vitro findings show that the S63845+vene-
toclax combination clearly increased apoptotic cell death
and reduced cell viability, with combination indexes (CI)
reaching a strong synergism (0.1 <CI <0.3) in almost all
cell lines (Online Supplementary Figures S2 and S3). This
effect was dose- and time-dependent, and short drug
exposures of 3-6 hours already triggered the apoptotic
effect (Figure 1A and B). Given the clinical interest of the
addition of dexamethasone in the current backbone of
MM treatment, the triple combination of S63845+vene-
toclax+dexamethasone was also evaluated.
Dexamethasone clearly increased the efficacy of both
S63845 and venetoclax, and the triple combination
showed an even stronger synergism than the
S63845+venetoclax doublet in MM.1S (best CI=0.054)
and RPMI-8226 (best CI=0.099) cells (Online
Supplementary Figure S4A and B). 
The anti-tumoral effect of S63845 and venetoclax was
further investigated ex vivo in cells isolated from eight
MM patients. Patients 1 and 2 harbored the t(11;14)
translocation, Patients 3 to 7 had 1q gain, and Patient 8
did not bear any of those cytogenetic alterations. S63845
in monotherapy was active in almost all patients (Online
Supplementary Figure S5A), although those patients with
1q amplification (thus harboring the locus of the MCL1
gene) were significantly more sensitive to this agent
(Student t-test, P<0.05) (Online Supplementary Figure S5B).
Whether 1q amplification is a bona-fide marker of
response to MCL-1 inhibitors is being tested in ongoing
preclinical and clinical studies. On the other hand, only
Patient 2 bearing the t(11;14) translocation was clearly
sensitive to venetoclax as single agent (Online
Supplementary Figure S5C). This situation is consistent
with the clinical data in which less than half of the
t(11;14) patients responded to venetoclax.5 Finally, in 5 of
the 8 evaluated patients (Patients 1, 2, 3, 7 and 8), the
combination enhanced the apoptotic induction of both
agents in monotherapy, but, interestingly, this was partic-
ularly evident in Patient 2 [venetoclax responder harbor-
ing the t(11;14) translocation] and Patient 8 [insensitive
to both drugs in monotherapy without t(11;14) transloca-
tion or +1q gain alterations] (Figure 1C). The toxicity on
normal lymphocytes was clearly lower than that on
tumor cells, suggesting a therapeutic window for both
drugs (Figure 1C and Online Supplementary Figure S5A-C).
Next, we explored the mechanism of action of the
S63845+venetoclax combination. BIM is a pro-apoptotic
protein which has already been shown to be involved in
the mechanism of action of S63845 and venetoclax in
monotherapy.12-14 Accordingly, using CRISPR/Cas9 gene
editing in MM.1S cells, we selected BIM knock-out
clones for 2 of the 3 major BIM isoforms (BIMEL and
BIML), which showed notably decreased sensitivity to the
S63845+venetoclax combination (Figure 2A). Since these
data prove the involvement of BIM in the mechanism of
action of the double combination, the binding of MCL-1,
BCL-2 and BCL-XL anti-apoptotic proteins to BIM was
next explored in the MM.1S and KMS12-BM cell lines
(Figure 2B and C). S63845 treatment clearly disrupted
MCL-1/BIM complexes, but also induced a compensa-
tory increase in BCL-2/BIM complexes over control levels
in both cell lines. BCL-XL/BIM complexes were also
increased after S63845 treatment in the MM.1S cell line,
but these complexes were absent in KMS12-BM cells.
These results imply that S63845 treatment may change
MM-cell dependence from MCL-1 to BCL-2, and also to
BCL-XL in cells particularly dependent on this protein,
thus suggesting a potential mechanism of resistance. On
the other hand, and consistent with previous reports,2,13
venetoclax impaired the formation of BCL-2/BIM com-
plexes and also increased the binding of MCL-1 to BIM
over control levels in KMS12-BM cells and the binding of
both MCL-1 and BCL-XL to BIM in MM.1S cells, suggest-
ing a parallel situation to that observed with S63845.
Importantly, after treatment with the S63845+venetoclax
combination, BCL-2/BIM complexes remained low in
both cell lines tested. However, in MM.1S cells, MCL-1
was still able to interact with BIM, although to a lesser
extent than with venetoclax in monotherapy, thereby
diminishing the previously described venetoclax escape
mechanism. Regarding BCL-XL/BIM complexes, their
increase with S63845 and venetoclax treatments in
monotherapy was not further potentiated by the double
combination. Whole cell lysates did not show major
changes on MCL-1, BCL-2, BCL-XL and BIM levels in
MM.1S and KMS12-BM cells treated with S63845 and
venetoclax alone and in combination (Figure 2B and C).
Finally, we immunoprecipitated MCL-1 and BCL-2 anti-
apoptotic proteins, and analyzed BIM binding by
immunoblotting (Online Supplementary Figure S6A and B);
the results obtained were in accordance with those from
BIM immunoprecipitation. MCL-1/NOXA and 
BCL-2/PUMA complexes were also evaluated, but low
expression of these pro-apoptotic proteins precluded
evaluation of their role in response to the drugs (data not
shown).
Furthermore, the efficacy of S63845+venetoclax was
explored in vivo in an aggressive disseminated model of
MM. The double treatment delayed tumor growth, and
in contrast to the agents in monotherapy, produced a sta-
tistically significant benefit with respect to the control
from day 19 onwards (Figure 3A). Of note, at day 32, a
mouse treated with S63845+venetoclax, despite only
having a relatively localized bioluminescence signal,
developed hind-limb paralysis and was euthanized for
humane reasons (Figure 3B). Nevertheless, the efficacy in
controlling tumor growth translated into improved sur-
vival of mice treated with S63845+venetoclax, with a
median survival of 60 days (range: 32-88 days) compared
with 51 days for S63845 (range: 38-55 days) and 46 days
for venetoclax (range: 41-55 days) (Figure 3C), although
these differences were not statistically significant.
Remarkably, none of the treatments caused a significant
reduction in body weight (Online Supplementary Figure
S7A) or other signs of toxicity. It should be noted that
S63845 has weaker affinity for murine MCL-1,11 and
therefore other models15would be required to better eval-
uate the safety margins of this combination.
Similarly to in vitro studies, we also evaluated the activ-
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ity and toxicity of the triple combination of
S63845+venetoclax+dexamethasone in the previously
mentioned in vivo disseminated model of MM. The triple
combination induced approximately 30 days delay in
tumor growth compared with the control group (Figure
3D). Most importantly, the tolerability of this triple com-
bination was excellent, without significant body weight
loss (Online Supplementary Figure S7B) or other signs of
toxicity.
Finally, we performed mechanistic studies on tumor
cells from large RPMI-8226 plasmacytomas excised 24
hours after one dose of treatment (Figure 3E). In accor-
dance with in vitro data, treatment with S63845 and vene-
toclax in monotherapy, respectively, impaired the bind-
ing of MCL-1 and BCL-2 to the pro-apoptotic protein
BIM. Moreover, there was a compensatory upregulation
of MCL-1/BIM complexes in tumors from mice treated
with venetoclax, but no increase in BCL-2/BIM complex-
es in tumors from mice treated with S63845. Remarkably,
the S63845+venetoclax combination completely disrupt-
ed BCL-2/BIM complexes and was able to counteract the
compensatory upregulation of MCL-1 bound to BIM in
tumors treated with venetoclax in monotherapy. Thus, in
vivo, benefit is observed with the double combination rel-
ative to the disruption of BIM complexes with MCL-1
and BCL-2. 
In conclusion, we have shown the high preclinical effi-
cacy and synergism of the S63845 and venetoclax combi-
nation on MM cells, mediated at least in part by the
simultaneous inhibition of the binding of MCL-1 and
BCL-2 to BIM. Our preclinical results provide a strong
rationale for the clinical investigation of the combination
of an MCL-1 inhibitor with venetoclax for the treatment
of MM patients. In addition, based on the preliminary
results obtained with the triple combination, the addition
of dexamethasone may also be considered. 
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